New York-based healthcare technology company, Aetion, which makes an analytics platform to assess real-world evidence from a range of sources, has raised $11.2 million in Series A funding. Flare Capital Partners, a VC firm focused on early stage health technology and services, led the round, and Lakestar also contributed.
Aetion’s Evidence Platform, which the company launched in 2015, allows payers, providers, medical device makers, and biopharma customers, as well as academic institutions, to analyze data from everyday clinical and financial interactions in healthcare including claims, EHRs, registries and clinical trials. The company will used the new funding to continue building on the platform’s capabilities as well as expand its commercial use.
The company was founded in 2013 by Harvard Medical School faculty members and big data experts, and aims to help payers and providers collaborate in real-time with pharma and device companies as they develop, test and launch new therapies.
“With the healthcare industry moving toward data-driven, value-based care, essential evidence is a necessity for assessing the expected and realized value of medical products and treatments,” Aetion President, cofounder and Chief Scientific Officer Jeremy A. Rassen said in a statement. “Our platform combines modern analytic methods with rapid-cycle computing technology to generate the transparent,…